triindeneylphosphine | 957916-90-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚和异茚
• 英文名称: triindeneylphosphine
• 英文别名: triindenylphosphine；Triindenylphosphin；tris(1H-inden-1-yl)phosphane
• CAS: 957916-90-4
• 化学式: C₂₇H₂₁P
• 分子量: 376.438
• InChiKey: HINPQOBPEOFQBT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.1
• 重原子数：
  28
• 可旋转键数：
  3
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  、 、 triindeneylphosphine 、 三甲氧基磷 以 neat (no solvent) 为溶剂， 生成 、
  参考文献：
  名称：

  Unexpected migration of the indenyl ligand in the reaction of alkynyl(η5-indenyl)iron complexes with phosphanes and phosphites from iron to the alkynyl group

  摘要：

  Novel indenylvinylidene iron complexes are formed in the reaction of alkynyl(η5-indenyl)iron complexes with phosphites and phosphanes in large excess by an intermolecular transfer of the indenyl ligand from iron to the Cβ atom of the alkynyl ligand; mechanistic studies indicate that the reaction proceeds by a radical pathway.

  DOI：

  10.1039/a902785h

文献信息

• CYCLIC AMINE DERIVATIVE HAVING SUBSTITUTED ALKYL GROUP
  申请人：Kimura Tomio

  公开号：US20090306059A1

  公开（公告）日：2009-12-10

  A compound having the general formula (I), pharmacologically acceptable salts thereof or prodrugs thereof: [wherein R 1 represents a hydrogen atom, a C1-C6 alkyl group which may be substituted, a C3-C6 cycloalkyl group which may be substituted, a C1-C6 alkoxy group which may be substituted or a C6-C10 aryl group which may be substituted; R 2 represents a hydrogen atom, a halogen atom, a carboxy group, a C2-C7 alkoxycarbonyl group, a carbamoyl group, a cyano group, a C1-C6 alkyl group, a halogeno C1-C6 alkyl group, a C1-C6 alkyl group substituted by a heteroaryl group, a C1-C6 alkoxy group, a halogeno C1-C6 alkoxy group, a hydroxy C1-C6 alkyl group, a C2-C12 alkoxyalkyl group, a formyl group, a C2-C7 alkanoyl group, a C4-C7 cycloalkylcarbonyl group, a C2-C7 alkylcarbamoyl group, a di(C1-C6 alkyl)carbamoyl group, a group of formula R 4 —CO—CR 5 R 6 —(CH 2 ) m —, a group of formula R 7 —CO—(CH 2 ) l —N(R 8 )— or a sulfamoyl C1-C6 alkyl group; R 3 represents a substituted C1-C6 alkyl group, a heterocyclyl group or a heterocyclyl group substituted with 1 to 5 substituents; X 1 , X 2 , X 3 , X 4 and X 5 each independently represents a hydrogen atom, a halogen atom, an amino group, a carboxy group, a carbamoyl group, a cyano group, a nitro group, a C1-C6 alkyl group, a halogeno C1-C6 alkyl group, a C1-C6 alkoxy group, or a halogeno C1-C6 alkoxy group; and n represents an integer of 0 to 2].

  具有通式（I）的化合物，其药学上可接受的盐或前药： [其中R1代表氢原子，可能被取代的C1-C6烷基，可能被取代的C3-C6环烷基，可能被取代的C1-C6烷氧基或可能被取代的C6-C10芳基； R2代表氢原子，卤原子，羧基，C2-C7烷氧羰基，氨基甲酰基，氰基，C1-C6烷基，卤代C1-C6烷基，被杂环芳基取代的C1-C6烷基，C1-C6烷氧基，卤代C1-C6烷氧基，羟基C1-C6烷基，C2-C12烷氧基烷基，甲酰基，C2-C7烷酰基，C4-C7环烷基羰基，C2-C7烷基氨基甲酰基，二(C1-C6烷基)氨基甲酰基，通式R4—CO—CR5R6—(CH2)m—的基团，通式R7—CO—( )l—N(R8)—或磺胺基C1-C6烷基； R3代表取代的C1-C6烷基，杂环烷基或带有1至5个取代基的取代的杂环烷基； X1、X2、X3、X4和X5分别独立地代表氢原子，卤原子，氨基，羧基，氨基甲酰基，氰基，硝基，C1-C6烷基，卤代C1-C6烷基，C1-C6烷氧基或卤代C1-C6烷氧基；以及 n代表0至2的整数。
• Benzylamine analogues
  申请人：SANKYO COMPANY, LIMITED

  公开号：US20040067981A1

  公开（公告）日：2004-04-08

  A compound of the formula (I): 1 wherein R 1 represents C 1 -C 6 alkyl, amino (C 1 -C 6 alkyl)amino, di(C 1 -C 6 alkyl) amino or a nitrogen-containing saturated heterocyclic; R 2 and R 3 are the same or different and represent hydrogen or C 1 -C 6 alkyl; R a represents C 1 -C 6 alkyl or C 2 -C 6 alkenyl or together with R 2 represents a C 1 -C 3 alkylene; Arom represents aryl or heteroaryl; A represents a C 1 -C 6 alkylene; E represents a single bond, oxygen, sulfur or R 4 NR 4 —, wherein R 4 is hydrogen or C 1 -C 7 alkenoyl; X 1 and X 2 are the same or different and represent oxygen or sulfur; or a pharmacologically acceptable salt or ester thereof. The compound has superior acetylcholinesterase inhibitory action and selective serotonin reuptake inhibitory action, and is useful for treating or preventing Alzheimer's disease, depression, Huntington's chorea, Pick's disease, tardive dyskinesia, compulsive disorders or panic disorders.

  化合物的化学式为（I）：1，其中R1代表C1-C6烷基，氨基（C1-C6烷基）氨基，二（C1-C6烷基）氨基或含氮饱和杂环；R2和R3相同或不同，代表氢或C1-C6烷基；R代表C1-C6烷基或C2-C6烯基或与R2一起代表C1-C3烷基；Arom代表芳基或杂芳基；A代表C1-C6烷基；E代表单键，氧，硫或R4NR4—，其中R4为氢或C1-C7烯酰基；X1和X2相同或不同，代表氧或硫；或其药学上可接受的盐或酯。该化合物具有优异的乙酰胆碱酯酶抑制作用和选择性5-羟色胺再摄取抑制作用，并可用于治疗或预防阿尔茨海默病、抑郁症、亨廷顿舞蹈症、皮克病、迟发性运动障碍、强迫性障碍或惊恐障碍。
• Benzamidine derivatives
  申请人：SANKYO COMPANY, LIMITED

  公开号：US20040248981A1

  公开（公告）日：2004-12-09

  Benzamidine derivatives of formula (I) or pharmaceutically acceptable salts thereof exhibit excellent inhibitory activity against factor Xa and are useful for treating or preventing blood coagulation disorders: 1 wherein R 1 represents a hydrogen atom, a halogen atom, an alkyl group or a hydroxyl group; R 2 represents a hydrogen atom, a halogen atom or an alkyl group, R 3 represents a hydrogen atom, an optionally substituted alkyl group, an aralkyl group, an optionally substituted alkanoyl group or an optionally substituted alkylsulfonyl group, R 4 and R 5 are the same as or different from each other and each represent a hydrogen atom, a halogen atom, an optionally substituted alkyl group, an alkoxy group, a carboxyl-group, an alkoxycarbonyl group or an optionally substituted carbamoyl group, and R 6 represents a substituted pyrrolidine group or substituted piperidine group.

  公式（I）中的苯甲酰胺衍生物或其药学上可接受的盐表现出优异的抑制因子Xa的活性，可用于治疗或预防血液凝固障碍：其中R1代表氢原子，卤原子，烷基或羟基；R2代表氢原子，卤原子或烷基，R3代表氢原子，可选取代的烷基，芳基烷基，可选取代的烷酰基或可选取代的烷基磺酰基，R4和R5相同或不同，每个代表氢原子，卤原子，可选取代的烷基，烷氧基，羧基，烷氧羰基或可选取代的氨基甲酰基，而R6代表取代的吡咯烷基或取代的哌嗪烷基。
• Cyclic amine derivative having heteroaryl ring
  申请人：Kimura Tomio

  公开号：US20060270706A1

  公开（公告）日：2006-11-30

  A compound having the general formula (I) wherein R 1 represents C1-C6 alkyl, etc., R 2 represents hydrogen, C2-C7 alkanoyl, C7-C11 arylcarbonyl, the formula R 4 —(CH 2 ) 1 —, etc., R 3 represents C6-C10 aryl, etc., X 1 , X 2 , X 3 , X 4 and X 5 each independently represents hydrogen, halogen, etc., and n represents an integer of 0 to 2, pharmacologically acceptable salts thereof or prodrugs thereof. They have excellent inhibition of platelet activation, etc. and are useful as a prophylactic or therapeutic agents for diseases related to thrombus or embolus formation.

  化合物具有通式（I），其中R1代表C1-C6烷基等，R2代表氢，C2-C7酰基，C7-C11芳基羰基，公式R4 -（CH2）1-等，R3代表C6-C10芳基等，X1，X2，X3，X4和X5各自独立地代表氢，卤素等，n代表0到2的整数，其药学上可接受的盐或前药。它们具有优异的抑制血小板活化等作用，并可用作与血栓或栓塞形成有关的疾病的预防或治疗剂。
• ISOXAZOLE DERIVATIVES
  申请人：SANKYO COMPANY LIMITED

  公开号：EP0885891A1

  公开（公告）日：1998-12-23

  The isoxazole derivatives having the following general formula: [wherein R1 represents an optionally substituted aryl group or aromatic heterocyclic group; R2 represents a hydrogen atom, a halogen atom, an optionally substituted alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a cycloalkenyl group, an alkoxy group, a cyano group, a carboxyl group, an alkanoyl group, an alkoxycarbonyl group or an optionally substituted carbamoyl group; R3 represents an optionally substituted amino group or a saturated heterocyclic group; X represents an oxygen atom or a sulfur atom; n is an integer of from 2 to 6] has an excellent monoamine oxidase inhibitory activity, and is useful as a therapeutic agent or a preventive agent against nervous diseases such as depression.

  具有以下通式的异噁唑衍生物： [其中 R1 代表任选取代的芳基或芳香杂环基团；R2 代表氢原子、卤素原子、任选取代的烷基、烯基、炔基、环烷基、环烯基、烷氧基、氰基、羧基、烷酰基、烷氧羰基或任选取代的氨基甲酰基；R3 代表任选取代的氨基或饱和杂环基团；X 代表氧原子或硫原子；n 为 2 至 6 的整数]具有极佳的单胺氧化酶抑制活性，可用作治疗剂或预防剂，防治抑郁症等神经疾病。